{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:46:07Z","timestamp":1777387567519,"version":"3.51.4"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"5-6","license":[{"start":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T00:00:00Z","timestamp":1730851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T00:00:00Z","timestamp":1730851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005788","name":"Medical University of Vienna","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005788","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Klin Wochenschr"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>Summary<\/jats:title>\n          <jats:p>Amyloid-beta (A\u03b2) antibody treatment has emerged as a\u00a0promising approach for the treatment of Alzheimer\u2019s disease (AD), targeting the accumulation of A\u03b2 plaques, which are a\u00a0hallmark of the disease. This review provides an update on recent clinical trial data, highlighting the efficacy and safety of various antibodies targeting A\u03b2. Recent trials have demonstrated that certain A\u03b2 antibodies can reduce amyloid plaques and slow cognitive decline in patients with early AD. Key findings from trials of drugs are discussed, including their mechanisms of action, dosing regimens, and observed side effects. The potential for A\u03b2 antibody therapy to be integrated into routine clinical practice is also explored. While A\u03b2 antibody therapy represents a\u00a0significant advancement in AD treatment, ongoing research is needed to optimize their use and understand their long-term impact. This review underscores the importance of personalized medicine in AD and the need for continued innovation in therapeutic strategies.<\/jats:p>","DOI":"10.1007\/s00508-024-02466-7","type":"journal-article","created":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T18:04:50Z","timestamp":1730916290000},"page":"182-188","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Amyloid-beta antibody treatment in Alzheimer\u2019s disease"],"prefix":"10.1007","volume":"137","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4688-8482","authenticated-orcid":false,"given":"Elisabeth","family":"St\u00f6gmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reinhold","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,6]]},"reference":[{"issue":"1","key":"2466_CR1","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13195-017-0283-5","volume":"9","author":"PS Aisen","year":"2017","unstructured":"Aisen\u00a0PS, Cummings\u00a0J, Jack\u00a0CR Jr, Morris\u00a0JC, Sperling\u00a0R, Fr\u00f6lich\u00a0L, Jones\u00a0RW, Dowsett\u00a0SA, Matthews\u00a0BR, Raskin\u00a0J, Scheltens\u00a0P, Dubois\u00a0B. On the path to 2025: understanding the Alzheimer\u2019s disease continuum. Alzheimers Res Ther. 2017;9(1):60.","journal-title":"Alzheimers Res Ther"},{"issue":"s1","key":"2466_CR2","doi-asserted-by":"publisher","first-page":"567","DOI":"10.3233\/JAD-179941","volume":"64","author":"EN Cline","year":"2018","unstructured":"Cline\u00a0EN, Bicca\u00a0MA, Viola\u00a0KL, Klein\u00a0WL. The Amyloid\u2011\u03b2 Oligomer Hypothesis: Beginning of the Third Decade. J\u00a0Alzheimers Dis. 2018;64(s1):567\u2013S610.","journal-title":"J Alzheimers Dis"},{"issue":"4","key":"2466_CR3","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s00115-012-3688-1","volume":"84","author":"H Braak","year":"2013","unstructured":"Braak\u00a0H, Feldengut\u00a0S, Del Tredici\u00a0K. Pathogenese und Pr\u00e4vention des M.\u00a0Alzheimer: Wann und auf welche Weise beginnt der pathologische Prozess? [Pathogenesis and prevention of Alzheimer\u2019s disease: when and in what way does the pathological process begin? Nervenarzt. 2013;84(4):477\u201382.","journal-title":"Nervenarzt"},{"issue":"4","key":"2466_CR4","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1055\/s-0033-1359319","volume":"33","author":"C Oboudiyat","year":"2013","unstructured":"Oboudiyat\u00a0C, Glazer\u00a0H, Seifan\u00a0A, Greer\u00a0C, Isaacson\u00a0RS. Alzheimer\u2019s disease. Semin Neurol. 2013;33(4):313\u201329. Sep.","journal-title":"Semin Neurol"},{"issue":"6555","key":"2466_CR5","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1126\/science.abi6401","volume":"373","author":"DJ Selkoe","year":"2021","unstructured":"Selkoe\u00a0DJ. Treatments for Alzheimer\u2019s diseaseemerge. Science. 2021;373(6555):624\u20136. https:\/\/doi.org\/10.1126\/science.abi6401.","journal-title":"Science"},{"issue":"2","key":"2466_CR6","doi-asserted-by":"publisher","first-page":"197","DOI":"10.14283\/jpad.2022.30","volume":"9","author":"S Budd Haeberlein","year":"2022","unstructured":"Budd Haeberlein\u00a0S, Aisen\u00a0PS, Barkhof\u00a0F, Chalkias\u00a0S, Chen\u00a0T, Cohen\u00a0S, Dent\u00a0G, Hansson\u00a0O, Harrison\u00a0K, von Hehn\u00a0C, Iwatsubo\u00a0T, Mallinckrodt\u00a0C, Mummery\u00a0CJ, Muralidharan\u00a0KK, Nestorov\u00a0I, Nisenbaum\u00a0L, Rajagovindan\u00a0R, Skordos\u00a0L, Tian\u00a0Y, van Dyck\u00a0CH, Vellas\u00a0B, Wu\u00a0S, Zhu\u00a0Y, Sandrock\u00a0A. Two Randomized Phase\u00a03 Studies of Aducanumab in Early Alzheimer\u2019s Disease. J\u00a0Prev Alzheimers Dis. 2022;9(2):197\u2013210.","journal-title":"J Prev Alzheimers Dis"},{"issue":"1","key":"2466_CR7","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck\u00a0CH, Swanson\u00a0CJ, Aisen\u00a0P, Bateman\u00a0RJ, Chen\u00a0C, Gee\u00a0M, Kanekiyo\u00a0M, Li\u00a0D, Reyderman\u00a0L, Cohen\u00a0S, Froelich\u00a0L, Katayama\u00a0S, Sabbagh\u00a0M, Vellas\u00a0B, Watson\u00a0D, Dhadda\u00a0S, Irizarry\u00a0M, Kramer\u00a0LD, Iwatsubo\u00a0T. Lecanemab in Early Alzheimer\u2019s Disease. N\u00a0Engl J Med. 2023;388(1):9\u201321.","journal-title":"N Engl J Med"},{"key":"2466_CR8","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","volume":"13","author":"CJ Swanson","year":"2021","unstructured":"Swanson\u00a0CJ, Zhang\u00a0Y, Dhadda\u00a0S, et\u00a0al. A\u00a0randomized, double-blind, phase\u00a02b proof-of-concept clinical trial in early Alzheimer\u2019s disease with lecanemab, an anti-A\u03b2 protofibril antibody. Alz Res Therapy. 2021;13:80. https:\/\/doi.org\/10.1186\/s13195-021-00813-8.","journal-title":"Alz Res Therapy"},{"issue":"1","key":"2466_CR9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.14283\/jpad.2020.68","volume":"8","author":"G Klein","year":"2021","unstructured":"Klein\u00a0G, Delmar\u00a0P, Kerchner\u00a0GA, Hofmann\u00a0C, Abi-Saab\u00a0D, Davis\u00a0A, Voyle\u00a0N, Baudler\u00a0M, Fontoura\u00a0P, Doody\u00a0R. Thirty-Six-Month Amyloid Positron Emission Tomography Results Show Continued Reduction in Amyloid Burden with Subcutaneous Gantenerumab. J\u00a0Prev Alzheimers Dis. 2021;8(1):3\u20136.","journal-title":"J Prev Alzheimers Dis"},{"key":"2466_CR10","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.13239","author":"JR Sims","year":"2023","unstructured":"Sims\u00a0JR, Zimmer\u00a0JA, Evans\u00a0CD, et\u00a0al. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA. 2023; https:\/\/doi.org\/10.1001\/jama.2023.13239.","journal-title":"JAMA"},{"issue":"18","key":"2466_CR11","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","volume":"384","author":"MA Mintun","year":"2021","unstructured":"Mintun\u00a0MA, Lo\u00a0AC, Duggan Evans\u00a0C, Wessels\u00a0AM, Ardayfio\u00a0PA, Andersen\u00a0SW, Shcherbinin\u00a0S, Sparks\u00a0J, Sims\u00a0JR, Brys\u00a0M, Apostolova\u00a0LG, Salloway\u00a0SP, Skovronsky\u00a0DM. Donanemab in Early Alzheimer\u2019s Disease. N\u00a0Engl J Med. 2021;384(18):1691\u2013704. https:\/\/doi.org\/10.1056\/NEJMoa2100708.","journal-title":"N Engl J Med"},{"issue":"3","key":"2466_CR12","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1001\/jamaneurol.2021.5205","volume":"79","author":"M Filippi","year":"2022","unstructured":"Filippi\u00a0M, Cecchetti\u00a0G, Spinelli\u00a0EG, Vezzulli\u00a0P, Falini\u00a0A, Agosta\u00a0F. Amyloid-Related Imaging Abnormalities and \u03b2\u2011Amyloid-Targeting Antibodies: A\u00a0Systematic Review. JAMA Neurol. 2022;79(3):291\u2013304. https:\/\/doi.org\/10.1001\/jamaneurol.2021.5205.","journal-title":"JAMA Neurol"},{"key":"2466_CR13","doi-asserted-by":"publisher","first-page":"357","DOI":"10.14283\/jpad.2023.44","volume":"10","author":"L Fr\u00f6lich","year":"2023","unstructured":"Fr\u00f6lich\u00a0L, Jessen\u00a0F. Lecanemab: Appropriate Use Recommendations\u2014A Commentary from a\u00a0European Perspective. J\u00a0Prev Alzheimers Dis. 2023;10:357\u20138. https:\/\/doi.org\/10.14283\/jpad.2023.44.","journal-title":"J Prev Alzheimers Dis"},{"key":"2466_CR14","doi-asserted-by":"publisher","first-page":"362","DOI":"10.14283\/jpad.2023.30","volume":"10","author":"J Cummings","year":"2023","unstructured":"Cummings\u00a0J, Apostolova\u00a0L, Rabinovici\u00a0GD, et\u00a0al. Lecanemab: Appropriate Use Recommendations. J\u00a0Prev Alzheimers Dis. 2023;10:362\u201377. https:\/\/doi.org\/10.14283\/jpad.2023.30.","journal-title":"J Prev Alzheimers Dis"},{"issue":"14","key":"2466_CR15","doi-asserted-by":"publisher","first-page":"1171681","DOI":"10.3389\/fneur.2023.1171681","volume":"5","author":"M Giorelli","year":"2023","unstructured":"Giorelli\u00a0M. Current and future perspectives of an early diagnosis of cognitive impairment. Front Neurol. 2023;5(14):1171681. https:\/\/doi.org\/10.3389\/fneur.2023.1171681.","journal-title":"Front Neurol"}],"container-title":["Wiener klinische Wochenschrift"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-024-02466-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00508-024-02466-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-024-02466-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T15:37:42Z","timestamp":1742485062000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00508-024-02466-7"}},"subtitle":["An update on recent data and outlook on implementation in clinical routine"],"short-title":[],"issued":{"date-parts":[[2024,11,6]]},"references-count":15,"journal-issue":{"issue":"5-6","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["2466"],"URL":"https:\/\/doi.org\/10.1007\/s00508-024-02466-7","relation":{},"ISSN":["0043-5325","1613-7671"],"issn-type":[{"value":"0043-5325","type":"print"},{"value":"1613-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,6]]},"assertion":[{"value":"5 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"E.\u00a0St\u00f6gmann received honoraria (lectures, advisory boards, consultations) from pharmaceutical companies: Biogen, Roche, Novo Nordisc, Eisai, Novartis, Sanofi and Lilly. She held leadership or a\u00a0fiduciary role in scientific societies (Austrian Alzheimer Association, the EAN scientific panel dementia). Her institution (Medical University of Vienna, Austria) received financial support for participation in clinical trials from Lundbeck, Biogen, Novo Nordisc and Roche Diagnostics. Her institution (Medical University of Vienna, Austria) received financial support by research grants for research in AD: Roche, Eisai, EU Horizon 2020 and the Austrian Alzheimer Association. R.\u00a0Schmidt received honoraria (lectures, advisory boards, consultations) from pharmaceutical companies: Biogen, Roche, Eisai, Novartis, Pfizer, Lundbeck , Merz Austria. He held leadership or a\u00a0fiduciary role in scientific societies (Austrian Alzheimer Association, the EAN scientific panel dementia, VasCog). His institution (Medical University of Graz, Austria) received financial support for participation in clinical trials from Lundbeck, Biogen, Novo Nordisc, Merz Austria, Pfizer, Novartis, Axon Neuroscience, Neuroscios. His institution (Medical University of Graz, Austria) received financial support by research grants for research in AD: Austrian Science Fund, Austrian Research Promotion Agency, National Institute of Health, USA, European Union Joint Programme-Neurodegenerative Disease Research, European Union-Era-Net Neuron and the Austrian Alzheimer Association.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}